Skip To Main Content
Matteo Barcella on Muck Rack

Matteo Barcella

As seen in: Nature, Science Magazine, Cell Reports Medicine, Cell Stem Cell
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Matteo

Contact Matteo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity

|
By Diego Gilioli, Simona Fusco, Teresa Tavella, Tatiana Volpari, Antonella Santoro, Martin Schönlein, Kety Giannetti, Edoardo Carsana, Nicolò Gualandi, Roberta Noberini, Chiara Brombin, Salvatore Russo, Sara Feola, Yvonne Giannoula, Janne Lehtiö, Tiina Sikanen, Markus Haapala, Laura Passerini, Giacomo Farina, Anastasia Conti, Lucrezia della Volpe, Matteo Barcella, Stefano Beretta, Federico Aletti, Matteo Giovanni Carrabba, Silvia Gregori, Chiara Bonini, Ivan Merelli, Fabio Ciceri, Vincenzo Cerullo, Tiziana Bonaldi, Luca Vago, Clemens A. Schmitt, Raffaella Di Micco, Rui M. M. Branca, Angela Andrisani, Alessia Zangari
| Nature Verified
Abstract Chemotherapy resistance and disease relapse are major determinants of treatment failure in acute myeloid leukemia (AML). Therapy-induced senescence (TIS) is one outcome of chemotherapy, but its immunological consequences in AML remain unclear. Here we show that ex vivo chemotherapy induces senescence in a subset of therapy-naïve AML samples.
Open in Who Shared Issue with article?

Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial

|
By Bernhard Gentner, Marica Eoli, Francesca Farina, Matteo Barcella, Alessia Capotondo, Antonio Francavilla, Matteo G. Carrabba, Valeria Ferla, Alessandro Bruno, Giorgia Alvisi, Eugenio Montini, Maria Grazia Bruzzone, Francesco Di Meco, Paolo Ferroli, Francesco Acerbi, Roberto Pallini, Quintino Giorgio D’Alessandris, Alessandro Olivi, Filippo Gagliardi, Silvia Snider, Pietro Mortini, Valeria Berno, Pietro Luigi Poliani, Carlo Russo, Fabio Ciceri, Luigi Naldini, Stefania Mazzoleni, Valentina Brambilla, Mariagrazia Garramone, Nadia Coltella, Leila Hadadi, Charlotte Capt, Valeria Cuccarini, Federico G. Legnani, Monica Patanè, Amleto Fiocchi, Gaetano Finocchiaro
| Nature Verified
Abstract Glioblastoma (GBM) is an immunologically cold brain tumor with poor outcome, characterized by a myeloid-driven immunosuppressive microenvironment. Here we report an interim analysis of a first-in-human phase 1/2a dose-escalation study evaluating Temferon—a genetically engineered autologous stem cell transplant designed to deliver interferon-α2 by means of myeloid progeny recruited to the GBM TME and locally activate antitumor immunity.
Open in Who Shared Issue with article?

Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells

|
By Federico Midena, Laura Alessandrini, Matteo Barcella, Francesco Gazzo, Emanuela Jacchetti, Edoardo Carsana, Roberta Vacca, Lucrezia della Volpe, Sergio Arévalo, Kety Giannetti, Erika Zonari, Francesca Ferrua, Giacomo Farina, Chiara Brombin, Federica Cugnata, Martina Fiumara, Teresa Tavella, Giulio Cerullo, Roberto Osellame, Samuele Ferrari, Ivan Merelli, Bernhard Gentner, Luigi Naldini, Alessandro Aiuti, Eugenio Montini, Raffaella Di Micco, Claudio Conci, Fabrizio Benedicenti, Dafne Barozzi, Martina Franchino, Leonardo Cherubin, Federico Fraschetta, Marina Radrizzani, Cristina Scielzo, Andrea Brendolan, Manuela T. Raimondi
| Cell Stem Cell Verified
STAR★Methods REAGENT or RESOURCESOURCEIDENTIFIER Antibodies Anti-8-oxo-2’deoxyguanosine Trevigen Cat#4354-MC-050; RRID: AB_1857195 Anti-alpha Tubulin antibody – Loading Control Abcam Cat#ab4074; RRID: AB_2288001 Anti-human CD11b PE (Clone M1/70) BioLegend Cat#101207; RRID: AB_312790 Anti-human CD13 BV421 (Clone WM15) BD Biosciences Cat#562596; RRID: AB_2737672 Anti-human CD133/1 PE-Vio 770 (Clone AC133) Miltenyi Biotec Cat#130-113-110; RRID: AB_2725939 Anti-human CD14 APC-Cy7 (Clone M5E2)...
Open in Who Shared Issue with article?
See all 4 articles